RecruitingNCT06642168

Sudden Cardiac Arrest Related to Sport in Young and Value of the Genetic Assessment: a French Prospective Register

Registre Prospectif français Des Morts Subites Chez Des Sportifs Jeunes


Sponsor

Rennes University Hospital

Enrollment

80 participants

Start Date

Oct 11, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The increased risk of sudden cardiac arrest (SCA) or sudden cardiac death (SCD) related to vigorous physical activity is well-documented. Currently, for young victims (under 35 years) of SCA/SCD, no etiology is found in 40 to 50% of cases after a standard medical assessment, leading to two important consequences. For the victim's family, it is difficult to understand and accept this tragic event, and the risk of it occurring in another family member is a source of concern. Medically, the absence of a known cause limits the ability to effectively prevent such events. The RESOUDRE study will be a national, prospective, observational registry of young victims (12-35 years) of sports-related SCA/SCD. All cases will undergo the recommended etiological assessment, including autopsy for SCA cases, along with whole exome genetic analysis and toxicological testing. In the event a genetic pathology is identified, a genetic evaluation will be offered to other family members, and appropriate medical care will be provided if necessary. The results of this study could significantly reduce the number of unexplained sport-related SCA/SCD cases and aid in preventing these incidents among affected families.


Eligibility

Min Age: 12 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Whole exome sequencing to detect myocardial genetic mutations (SCA group only) for people with sudden cardiac arrest and sudden cardiac death. The study is currently recruiting participants at 26 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICWhole exome sequencing to detect myocardial genetic mutations (SCA group only)

Whole exome sequencing to detect myocardial genetic mutations


Locations(26)

CHU Nîmes

Nîmes, France, France

APHP Hôpital Bichat

Paris, France, France

APHP Hôpital Européen Georges Pompidou

Paris, France, France

CHU Rennes

Rennes, France, France

CHU Bordeaux

Bordeaux, France

CHU Brest

Brest, France

CHU Caen

Caen, France

CHU Clermont-Ferrand

Clermont-Ferrand, France

APHP Hôpital Henri-Mondor

Créteil, France

CHU Dijon Bourgogne

Dijon, France

CHU de Grenoble Alpes

Grenoble, France

CHRU Lille

Lille, France

Hospices Civils de Lyon

Lyon, France

APHM Hôpitaux universitaires de Marseille

Marseille, France

CHRU Montpellier

Montpellier, France

CHRU Nancy

Nancy, France

CHU Nantes

Nantes, France

CHU de Nice

Nice, France

APHP Hôpital Pitié-Salpêtrière

Paris, France

CHU Poitiers

Poitiers, France

CHU Reims

Reims, France

CHU Rouen

Rouen, France

CHU Saint-Etienne

Saint-Etienne, France

CHRU Strasbourg

Strasbourg, France

CHU Toulouse

Toulouse, France

CHRU Tours

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06642168


Related Trials